GlobeNewswire: Immuron Limited Contains the last 10 of 155 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:14:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/07/2842034/0/en/Immuron-Announces-Positive-Results-Support-Travelan-progress-to-Phase-3-Clinical-Trials-in-the-US.html?f=22&fvtc=4&fvtv=27652Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US2024-03-07T11:00:00Z<![CDATA[Highlights:]]>https://www.globenewswire.com/news-release/2024/02/21/2832555/0/en/Immuron-Presentation-Australian-Biologics-Festival-2024.html?f=22&fvtc=4&fvtv=27652Immuron Presentation Australian Biologics Festival 20242024-02-21T11:00:00Z<![CDATA[MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia.]]>https://www.globenewswire.com/news-release/2024/02/13/2828057/0/en/Immuron-achieves-record-Travelan-sales.html?f=22&fvtc=4&fvtv=27652Immuron achieves record Travelan® sales2024-02-13T11:00:00Z<![CDATA[Highlights:]]>https://www.globenewswire.com/news-release/2024/02/08/2825820/0/en/Immuron-CEO-Steven-Lydeamore-Investor-Webinar-Presentation.html?f=22&fvtc=4&fvtv=27652Immuron CEO, Steven Lydeamore Investor Webinar Presentation2024-02-08T11:00:00Z<![CDATA[MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia.]]>https://www.globenewswire.com/news-release/2024/01/16/2809637/0/en/Immuron-achieves-record-half-yearly-Travelan-sales.html?f=22&fvtc=4&fvtv=27652Immuron achieves record half yearly Travelan® sales2024-01-16T11:00:00Z<![CDATA[Highlights:]]>https://www.globenewswire.com/news-release/2023/12/22/2800503/0/en/Immuron-Clinical-Trials-Update.html?f=22&fvtc=4&fvtv=27652Immuron Clinical Trials Update2023-12-22T11:00:00Z<![CDATA[Highlights:]]>https://www.globenewswire.com/news-release/2023/12/04/2789817/0/en/Immuron-Announces-First-Patients-Enrolled-in-Campylobacter-Challenge-Clinical-Study.html?f=22&fvtc=4&fvtv=27652Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study2023-12-04T11:00:00Z<![CDATA[Highlights:]]>https://www.globenewswire.com/news-release/2023/11/28/2786770/0/en/Immuron-CEO-Steven-Lydeamore-Investor-Webinar-Presentation.html?f=22&fvtc=4&fvtv=27652Immuron CEO, Steven Lydeamore Investor Webinar Presentation2023-11-28T11:33:14Z<![CDATA[MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST.]]>https://www.globenewswire.com/news-release/2023/11/13/2779605/0/en/Immuron-CEO-Steven-Lydeamore-Investor-Webinar-Presentation.html?f=22&fvtc=4&fvtv=27652Immuron CEO Steven Lydeamore Investor Webinar Presentation2023-11-13T23:00:00Z<![CDATA[MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST.]]>https://www.globenewswire.com/news-release/2023/10/30/2769063/0/en/Immuron-CEO-Steven-Lydeamore-presented-at-AusBioInvest.html?f=22&fvtc=4&fvtv=27652Immuron CEO Steven Lydeamore presented at AusBioInvest2023-10-30T11:21:17Z<![CDATA[MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia.]]>